Translational development of specialized NK cells for cancer immunotherapy
Ended Project Grant Awarded Last action
- Award ID
- R41CA235924
- Recipient
-
Indapta Therapeutics Inc. UEI FW7PJD4KQXC7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Assistance listing
- 93.396 Cancer Biology Research
- Completion date
- Originally
- Place of performance
- Seattle, WA 98121, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $300,000 |
Quick answers
Who received award R41CA235924?
R41CA235924 was awarded to Indapta Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on May 1, 2019.
How much is award R41CA235924 worth?
$300,000 has been obligated on R41CA235924.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award